Is OEM service available for this product?

Yes, OEM service is available for this product.

What are the available packaging options?

The product is available in 1kg/bag and 25kg/bag packaging.

What are the main active ingredients?

The active ingredients include glucose oxidase, modified montmorillonite, and mannan oligosaccharide.

Veterinary Feed Additive Toxin Binder Soluble Powder to Improve Animals Immunity

Name: Veterinary Feed Additive Toxin Binder Soluble Powder to Improve Animals Immunity
Brand: Henan Muxiang Biological Co., Ltd.
SKU: 1979273212

Henan, ChinaHenan Muxiang Biological Co., Ltd.

US$19.75-22.50

50 Bags

Sample price:US$2.00/kg.Request sample

Product profile

Customization

Available

Certification

ISO

Shape

Powder

Model NO.

powder

Function

Toxin Binder

Type

The Frist Class

Transport Package

25kg/Bag

Trademark

Moosun

Origin

China

HS Code

2309901000

Production Capacity

500tons/Month

Key features

High Efficacy Toxin Removal: Effectively removes more than 95% of mycotoxins in feed.

Immunity Improvement: Releases immunosuppression and improves animal immunity.

Liver Protection: Cracks mycotoxins in the body and protects animal livers.

Broad Application: Suitable for all ages of poultry and livestock.

High Adsorption Capacity: Modified montmorillonite increases adsorption capacity 2-3 times.

Long Shelf Life: Product remains effective for 18 months when stored properly.

Customizable Function: Function is customizable as a toxin binder.

Company profile

Henan Muxiang Biological Co., Ltd.

Henan, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2016-02-01 CertifiedNearest Port: Shanghai Port, Qingdao PortAverage Response Time: ≤10.67h CertifiedTerms of Payment: LC, T/T, D/P, etc.

AI-Powered supplier vetting

SummaryHenan Muxiang Biological Co., Ltd. is a China-based limited-company factory established in 2004, with 360 employees and operations in veterinary pharmaceuticals and animal-health products. The supplier reports seven pharmaceutical production lines, eight vaccine production lines, first-class production and inspection equipment, GMP management, ISO9001:2015 certification, and ISO/CNAS laboratory certification. Its R&D resources include more than 40 core personnel, over 30 of whom hold doctoral or master's degrees, while 21–30 quality-control staff are reported. The company exports to multiple global regions, has self-operated import and export rights, and states a one-month order-fulfillment period in both peak and off-peak seasons. Evidence supports capabilities in certification, innovation, production, and international operations. However, the provided information does not sufficiently establish after-sales service performance, financial credibility, customization execution, or specific customer cases.

Supplier typeThe supplier is identified as a limited company and a factory in the manufacturing industry, with its operating location in Henan, China. This indicates a direct manufacturing entity rather than only a trading or intermediary business.

CertificationsThe supplier reports a systematic GMP management system, ISO/CNAS laboratory international certification, and an ISO9001:2015 certificate. These stated certifications and quality systems provide explicit evidence of formal quality-management capability.

R&D capabilityThe supplier reports more than 40 core R&D personnel, including over 30 doctors or master's degree graduates, 20 years of preparation-technology experience among R&D engineers, and advanced R&D platforms such as a National Enterprise Technology Center, National Postdoctoral Research Station, and Academician Workstation. It also reports improving herbal active-ingredient extraction by more than 30% versus a traditional process, supporting a strong stated innovation profile.

Production capacityThe supplier reports seven pharmaceutical production lines and eight vaccine production lines, first-class production and inspection equipment, six production lines in a separate operational data field, and one-month order fulfillment in both peak and off-peak seasons. Although the line-count figures are not fully consistent across the slices, the evidence clearly supports substantial pharmaceutical and vaccine manufacturing capability.